288 related articles for article (PubMed ID: 32473650)
1. Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.
Nilssen Y; Brustugun OT; Eriksen MT; Haug ES; Naume B; Møller B
BMC Cancer; 2020 May; 20(1):488. PubMed ID: 32473650
[TBL] [Abstract][Full Text] [Related]
2. Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016.
Nilssen Y; Brustugun OT; Eriksen MT; Guren MG; Haug ES; Naume B; Schlichting E; Møller B
BMC Cancer; 2022 Feb; 22(1):220. PubMed ID: 35227226
[TBL] [Abstract][Full Text] [Related]
3. Equitable access to cancer patient pathways in Norway - a national registry-based study.
Olsen F; Jacobsen BK; Heuch I; Tveit KM; Balteskard L
BMC Health Serv Res; 2021 Nov; 21(1):1272. PubMed ID: 34823515
[TBL] [Abstract][Full Text] [Related]
4. Access denied: The relationship between patient insurance status and access to high-volume hospitals.
Nabi J; Tully KH; Cole AP; Marchese M; Cone EB; Melnitchouk N; Kibel AS; Trinh QD
Cancer; 2021 Feb; 127(4):577-585. PubMed ID: 33084023
[TBL] [Abstract][Full Text] [Related]
5. Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
Emerson MA; Banegas MP; Chawla N; Achacoso N; Alexeeff SE; Adams AS; Habel LA
Cancer Res; 2017 Dec; 77(23):6770-6776. PubMed ID: 29187399
[TBL] [Abstract][Full Text] [Related]
6. Use of Alternative Medicine for Cancer and Its Impact on Survival.
Johnson SB; Park HS; Gross CP; Yu JB
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922780
[TBL] [Abstract][Full Text] [Related]
7. Evaluating factors associated with unknown SEER Summary Stage 2000 derived from collaborative stage at central registry level.
Hsieh MC; Yu Q; Wu XC; Wohler B; Fan Y; Qiao B; Jemal A; Ajani UA
J Registry Manag; 2012; 39(3):101-6. PubMed ID: 23443453
[TBL] [Abstract][Full Text] [Related]
8. Survival patterns for the top four cancers in Canada: the effects of age, region and period.
Ugnat AM; Xie L; Semenciw R; Waters C; Mao Y
Eur J Cancer Prev; 2005 Apr; 14(2):91-100. PubMed ID: 15785312
[TBL] [Abstract][Full Text] [Related]
9. Decreasing variation in the use of hospice among older adults with breast, colorectal, lung, and prostate cancer.
Lackan NA; Ostir GV; Freeman JL; Mahnken JD; Goodwin JS
Med Care; 2004 Feb; 42(2):116-22. PubMed ID: 14734948
[TBL] [Abstract][Full Text] [Related]
10. Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage.
Nilssen Y; Strand TE; Fjellbirkeland L; Bartnes K; Brustugun OT; O'Connell DL; Yu XQ; Møller B
Int J Cancer; 2016 Mar; 138(6):1350-60. PubMed ID: 26421593
[TBL] [Abstract][Full Text] [Related]
11. [Waiting times for cancer care in four most frequent cancers in several French regions in 2011 and 2012].
Pourcel G; Ledesert B; Bousquet PJ; Ferrari C; Viguier J; Buzyn A
Bull Cancer; 2013 Dec; 100(12):1237-50. PubMed ID: 24158562
[TBL] [Abstract][Full Text] [Related]
12. Determinants of NCI Cancer Center attendance in Medicare patients with lung, breast, colorectal, or prostate cancer.
Onega T; Duell EJ; Shi X; Demidenko E; Goodman D
J Gen Intern Med; 2009 Feb; 24(2):205-10. PubMed ID: 19067086
[TBL] [Abstract][Full Text] [Related]
13. Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway.
Nilssen Y; Brustugun OT; Tandberg Eriksen M; Gulbrandsen J; Skaaheim Haug E; Naume B; Møller B
Cancer Epidemiol; 2019 Aug; 61():59-69. PubMed ID: 31153048
[TBL] [Abstract][Full Text] [Related]
14. Importance of comorbidity in head and neck cancer.
Piccirillo JF
Laryngoscope; 2000 Apr; 110(4):593-602. PubMed ID: 10764003
[TBL] [Abstract][Full Text] [Related]
15. A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results Program.
Mettlin CJ; Menck HR; Winchester DP; Murphy GP
Cancer; 1997 May; 79(10):2052-61. PubMed ID: 9149035
[TBL] [Abstract][Full Text] [Related]
16. Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence.
Cho H; Mariotto AB; Mann BS; Klabunde CN; Feuer EJ
Am J Epidemiol; 2013 Aug; 178(3):339-49. PubMed ID: 23825168
[TBL] [Abstract][Full Text] [Related]
17. Ethnoracial and social trends in breast cancer staging at diagnosis in Brazil, 2001-14: a case only analysis.
Dos-Santos-Silva I; De Stavola BL; Renna NL; Nogueira MC; Aquino EML; Bustamante-Teixeira MT; Azevedo E Silva G
Lancet Glob Health; 2019 Jun; 7(6):e784-e797. PubMed ID: 31097280
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of the National Program of Cancer Registries' Breast, Colon, and Prostate Cancer Patterns of Care Study.
McDavid K; Schymura MJ; Armstrong L; Santilli L; Schmidt B; Byers T; Steele CB; O'Connor L; Schlag NC; Roshala W; Darcy D; Matanoski G; Shen T; Bolick-Aldrich S;
Cancer Causes Control; 2004 Dec; 15(10):1057-66. PubMed ID: 15801489
[TBL] [Abstract][Full Text] [Related]
19. How representative are colorectal, lung, breast and prostate cancer patients responding to the National Cancer Patient Experience Survey (CPES) of the cancer registry population in England? A population-based case control study.
Alessy SA; Davies EA; Rawlinson J; Baker M; Lüchtenborg M
BMJ Open; 2019 Dec; 9(12):e034344. PubMed ID: 31848175
[TBL] [Abstract][Full Text] [Related]
20. Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer.
Akinyemiju T; Sakhuja S; Waterbor J; Pisu M; Altekruse SF
Cancer Med; 2018 Apr; 7(4):1183-1193. PubMed ID: 29479835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
